Literature DB >> 30115596

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.

Paula Cramer1, Julia von Tresckow2, Jasmin Bahlo2, Sandra Robrecht2, Petra Langerbeins2, Othman Al-Sawaf2, Anja Engelke2, Anna-Maria Fink2, Kirsten Fischer2, Eugen Tausch3, Till Seiler4, Ludwig Fischer von Weikersthal5, Holger Hebart6, Karl-Anton Kreuzer2, Sebastian Böttcher7, Matthias Ritgen8, Michael Kneba8, Clemens-Martin Wendtner9, Stephan Stilgenbauer3, Barbara Eichhorst2, Michael Hallek2.   

Abstract

BACKGROUND: Targeted agents such as the type II anti-CD20 antibody obinutuzumab and the B-cell lymphoma-2 antagonist venetoclax have shown impressive therapeutic activity in chronic lymphocytic leukaemia. The CLL2-BAG trial was initiated to investigate the combination of these two agents in patients with chronic lymphocytic leukaemia.
METHODS: In this ongoing multicentre, open-label, investigator-initiated phase 2 trial, patients (aged ≥18 years) with chronic lymphocytic leukaemia requiring treatment according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria and an Eastern Cooperative Oncology Group performance status of 0-2 were enrolled at 16 sites in Germany. Patients with a relevant tumour load (absolute lymphocyte count ≥25 000 cells per μL or lymph nodes with a diameter of ≥5 cm) received sequential treatment of debulking with two cycles of bendamustine (70 mg/m2 intravenously on days 1 and 2 of each of the two 28-day cycles), followed by induction and maintenance with obinutuzumab (1000 mg intravenously on days 1-2, 8, and 15 of the first induction cycle, every 4 weeks in induction cycles 2-6, and every 12 weeks in the maintenance phase) and oral venetoclax (starting in induction cycle 2 with 20 mg/day, with a weekly dose escalation over 5 weeks to the target dose of 400 mg/day). The primary endpoint was the proportion of patients achieving an overall response by investigator assessment at the end of induction treatment. All patients who received at least two induction cycles were included in the efficacy analyses and all patients who received at least one dose of study drug were included in the safety analyses. This study is registered with ClinicalTrials.gov, number NCT02401503.
FINDINGS: Between May 6, 2015, and Jan 4, 2016, 66 patients were enrolled (35 treatment naive and 31 with relapsed or refractory disease), three of whom were excluded from the efficacy analysis because they received fewer than two induction cycles. Of the remaining 63 patients in the efficacy-evaluable population, 34 patients (54%) were treatment naive and 29 (46%) had relapsed or refractory disease. At data cutoff (Feb 28, 2017), all patients had completed induction treatment. At the end of the induction, 60 (95%) of 63 patients (95% CI 87-99) had responded, including all 34 patients in the treatment-naive cohort and 26 [90%] of 29 relapsed or refractory patients. The most common grade 3-4 adverse events during debulking were neutropenia and anaemia (five [11%] of 47 patients each), and thrombocytopenia and infection (three [6%] each). The most common grade 3-4 adverse events during induction were neutropenia (29 [44%] of 66 patients), infection (nine [14%]), thrombocytopenia (eight [12%]), infusion-related reactions (five [8%]), and secondary primary malignancy (four [6%]). 89 serious adverse events, including 69 related to study treatment, were reported. These serious adverse events were also mainly infections (four cases in four patients during debulking and 18 cases in 11 patients during induction) and cytopenia (four cases in four patients during debulking and ten cases in seven patients in induction). Five relapsed or refractory patients died: three cases of sepsis were deemed related to study treatment, whereas two deaths from Richter's transformation were not.
INTERPRETATION: The sequential application of bendamustine and obinutuzumab combined with venetoclax caused no unexpected or cumulative toxicities. The high proportion of patients who achieved overall responses, both treatment-naive and relapsed or refractory patients irrespective of physical fitness and genetic risk factors, compare favourably to established chronic lymphocytic leukaemia therapies. Further follow-up will help to define whether the remissions with eradication of minimal residual disease achieved with this combination are durable after treatment discontinuation. FUNDING: F Hoffmann-La Roche and AbbVie.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30115596     DOI: 10.1016/S1470-2045(18)30414-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  33 in total

Review 1.  Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.

Authors:  Caspar da Cunha-Bang; Carsten Utoft Niemann
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

2.  A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.

Authors:  Anthony R Mato; Lindsey E Roeker; Toby A Eyre; Chadi Nabhan; Nicole Lamanna; Brian T Hill; Danielle M Brander; Paul M Barr; Frederick Lansigan; Bruce D Cheson; Arun K Singavi; Maryam Sarraf Yazdy; Nirav N Shah; John N Allan; Erica B Bhavsar; Joanna Rhodes; Kaitlin Kennard; Stephen J Schuster; AnnaLynn M Williams; Alan P Skarbnik; Andre H Goy; Julie M Goodfriend; Colleen Dorsey; Catherine C Coombs; Hande Tuncer; Chaitra S Ujjani; Ryan Jacobs; Allison M Winter; John M Pagel; Neil Bailey; Anna Schuh; Mazyar Shadman; Andrea Sitlinger; Hanna Weissbrot; Sivraj Muralikrishnan; Andrew Zelenetz; Amy A Kirkwood; Christopher P Fox
Journal:  Blood Adv       Date:  2019-05-28

Review 3.  On the architecture of translational research designed to control chronic lymphocytic leukemia.

Authors:  Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

4.  Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia.

Authors:  Kirsten Fischer; Othman Al-Sawaf; Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 5.  Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

Authors:  Ciara L Freeman; Laurie Sehn
Journal:  Curr Oncol Rep       Date:  2018-11-27       Impact factor: 5.075

6.  Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Authors:  Andrew W Roberts; Shuo Ma; Thomas J Kipps; Steven E Coutre; Matthew S Davids; Barbara Eichhorst; Michael Hallek; John C Byrd; Kathryn Humphrey; Lang Zhou; Brenda Chyla; Jacqueline Nielsen; Jalaja Potluri; Su Young Kim; Maria Verdugo; Stephan Stilgenbauer; William G Wierda; John F Seymour
Journal:  Blood       Date:  2019-04-25       Impact factor: 22.113

7.  Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?

Authors:  Maryam Sarraf Yazdy; Anthony R Mato; Bruce D Cheson
Journal:  Blood       Date:  2018-11-14       Impact factor: 22.113

8.  Relapsed disease and aspects of undetectable MRD and treatment discontinuation.

Authors:  Barbara Eichhorst; Moritz Fürstenau; Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 9.  Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.

Authors:  Herbert Eradat
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

10.  Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials.

Authors:  O Al-Sawaf; S Robrecht; J Bahlo; A M Fink; P Cramer; J V Tresckow; E Lange; M Kiehl; M Dreyling; M Ritgen; J Dürig; E Tausch; C Schneider; S Stilgenbauer; C M Wendtner; K Fischer; M Hallek; B Eichhorst
Journal:  Leukemia       Date:  2020-03-17       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.